| Title |
Efficacy of intrathecal chemotherapy in patients with central nervous system involvement of hematological malignancies: a retrospective analysis
|
|---|---|
| Published in |
Journal of Neuro-Oncology, April 2018
|
| DOI | 10.1007/s11060-018-2849-x |
| Pubmed ID | |
| Authors |
A. Dara, B. B. Mook, J. K. Doorduijn, M. J. van den Bent, A. G. Dinmohamed, J. E. C. Bromberg |
| Abstract |
Central nervous system (CNS) involvement, especially involvement of the cerebrospinal fluid (CSF), is common in several haematological malignancies. Intrathecal (IT) chemotherapy can be used to manage CSF involvement. Here we evaluated the effectiveness of IT chemotherapy among 80 patients with haematological malignancies and CSF localization who were treated with IT chemotherapy from 2001 to 2012. The majority of patients was diagnosed with diffuse large B-cell lymphoma (26%) or acute lymphoblastic leukaemia/lymphoblastic lymphoma (19%). After first-line IT chemotherapy, which mainly consisted of methotrexate (MTX) and corticosteroids, CSF complete response (CSF CR) was achieved in 76% of patients. 91% reached CSF CR when including second-line IT-chemotherapy. Clinical response was documented in 75%. Although most patients were additionally treated with systemic chemotherapy, response rate did not differ between patients treated with CNS-penetrating and CNS-non-penetrating drugs. CNS progression/relapse occurred in 40% of patients with median progression-free survival of 12.2 months. The median overall survival was 18.3 months; 55% of the patients died during follow-up. Our analysis shows a high response rate after first-line IT chemotherapy, but also a relatively high progression/relapse percentage. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 22 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 22 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 4 | 18% |
| Student > Doctoral Student | 3 | 14% |
| Student > Postgraduate | 2 | 9% |
| Researcher | 2 | 9% |
| Student > Bachelor | 2 | 9% |
| Other | 3 | 14% |
| Unknown | 6 | 27% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 9 | 41% |
| Nursing and Health Professions | 3 | 14% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 5% |
| Immunology and Microbiology | 1 | 5% |
| Unspecified | 1 | 5% |
| Other | 0 | 0% |
| Unknown | 7 | 32% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 April 2018.
All research outputs
#20,480,611
of 23,041,514 outputs
Outputs from Journal of Neuro-Oncology
#2,589
of 2,989 outputs
Outputs of similar age
#290,501
of 329,292 outputs
Outputs of similar age from Journal of Neuro-Oncology
#62
of 93 outputs
Altmetric has tracked 23,041,514 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,989 research outputs from this source. They receive a mean Attention Score of 4.2. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 329,292 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 93 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.